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Introduction: Using a type 2 hybrid effectiveness-implementation design, we aim to 44 
pilot a diabetic retinopathy (DR) care pathway in the public health system in Kerala to 45 
understand how it can be scaled up to and sustained in the whole state. 46 
Methods and analysis: Currently, there is no systematic DR screening programme in 47 
Kerala. Our intervention is a teleophthalmology pathway for people with diabetes in the 48 
non-communicable disease registers in 16 family health centres. The planned 49 
implementation strategy of the pathway will be developed based on the discrete Expert 50 
Recommendations for Implementing Change (ERIC) taxonomy. We will utilise both 51 
quantitative data from a cross-sectional study and qualitative data obtained from 52 
structured interviews, surveys and group discussions with stakeholders to report the 53 
effectiveness of the DR care pathway and evaluation of the implementation strategy.  54 
We will use logistic regression models to assess crude associations DR and STDR and 55 
fractional polynomials to account for the form of continuous covariates to predict uptake 56 
of DR screening. The primary effectiveness outcome is the proportion of patients in the 57 
non-communicable disease register with diabetes screened for DR over 12 months. 58 
Other outcomes include cost-effectiveness, safety, efficiency, patient satisfaction, 59 
timeliness and equity. The outcomes of evaluation of the implementation strategies 60 
include acceptability, feasibility, adoption, appropriateness, fidelity, penetration, costs 61 
and sustainability. Addition of more family health centres during the staggered initial 62 
phase of the programme will be considered as a sign of acceptability and feasibility. In 63 
the long term, the state-wide adoption of the DR care pathway will be considered as a 64 
successful outcome of the Nayanamritham study.  65 
 Ethics and Dissemination: The study was approved by Indian Medical Research Council 66 
(2018-0551) dated 13/03/2019. Study findings will be disseminated through scientific 67 









ARTICLE SUMMARY 75 
• This study will examine the clinical and cost effectiveness of a new diabetic retinopathy 76 
care pathway at the patient, clinician and service levels and evaluate the implementation 77 
strategy within a resource constrained environment. 78 
• This type 2 hybrid effectiveness-implementation study will use mixed methods as 79 
method of evaluation. 80 
• The specific actions in the implementation strategy are based on the Expert 81 
Recommendations for Implementing Change (ERIC) taxonomy 82 
• The study outlines the economic evaluation of the costs of the diabetic retinopathy care 83 
pathway.  84 
• The study is limited by the absence of a comparator due to lack of previous data on the 85 
























The triad of diabetes, blindness and poverty is an urgent problem that needs an effective 108 
response in the Development Assistance Committee-listed countries as these countries are 109 
home to 80% of people with diabetes. 1 Diabetic retinopathy (DR) is one of the most common 110 
complications of diabetes. 2 Sight-threatening diabetic retinopathy (STDR) is a common cause 111 
of blindness in working-age people and unless this condition is managed early, it has 112 
considerable impact on the quality of life and productivity of the person and their family, as well 113 
as substantial financial costs to health systems. 3  In its early stages, STDR may be 114 
asymptomatic. Therefore, DR screening programmes are essential to identify STDR to enable 115 
timely treatment. 4 In DR screening programmes in high income countries, people with diabetes 116 
are systematically screened using office-based retinal cameras and the retinal images are 117 
graded according to severity of DR by dedicated accredited screeners and graders. Patients 118 
with STDR are identified and referred to ophthalmologists for timely treatment with laser and/or 119 
intravitreal injections of anti-vascular endothelial growth factor. 4 In order to successfully reduce 120 
the risk of blindness due to DR in low-middle income countries (LMICs), without a well-121 
developed primary care infrastructure, the pathway needs to begin with systematically screening 122 
for diabetes, educating the public and healthcare professionals on early detection5 and timely 123 
treatment of STDR and the need to optimally treat the risk factors for DR such as 124 
hyperglycaemia, hypertension and hyperlipidemia. 2 Moreover, DR screening and treatment are 125 
challenging due to the required technology and technical expertise needed to grade retinal 126 
images and deliver costly treatment options, adding to the cost and complexity of the required 127 
interventions. 128 
 129 
Diabetes in Kerala 130 
Kerala is the most advanced state in India in terms of literacy, health, social uplift and 131 
demographic transition.6 This has been accompanied by high prevalence of diabetes. A recent 132 
report from Kerala suggests that one in five of the Kerala adult population may have diabetes.7 133 
The Government of Kerala launched the Aardram Mission in 2017 to transform and gear up the 134 
State’s public health care system to achieve the Sustainable Development Goals (SDGs) in 135 
phases with short term goals on building infrastructure and quality care services. The 136 
overarching objectives of the Aardram Mission included providing equitable, affordable and 137 
quality care to citizens from all socio-economic strata; strengthening the public care system by 138 
 
 5 
decentralising healthcare from the secondary and tertiary level to primary care-led services and 139 
initiating preventive medicine to address the impact of non-communicable diseases, especially 140 
hypertension and diabetes. Primary care centres have been converted to family health centres 141 
(FHCs) with three doctors and four nurses in each family health centre assigned to provide 142 
individual care plans to the allocated population whose records are tracked through a recently 143 
established Electronic Health Records (EHR) called eHealth. The transformation of primary care 144 
with a focus on non-communicable diseases provided the backdrop to the implementation of a 145 
DR care pathway.   146 
           147 
The rationale for a complex DR care pathway 148 
The Government of Kerala is pressing forward to achieve universal health coverage and 149 
address the sustained development goals (SDG) goals on poverty (SDG 1), health access 150 
(SDG 3), education (SDG 4) and gender equality (SDG 5). 8, 9 Therefore, there is an urgent 151 
need to tackle the complications of diabetes. Systematic DR screening has been shown to be 152 
effective in reducing blindness. 3 However, in high income countries, DR screening is achieved 153 
by dedicated services due to the technicalities and expertise required in DR screening and 154 
evaluation. 10-12  Introducing an isolated DR care pathway will not be sufficient to address the 155 
challenge in LMICs as these countries need to initiate holistic screening service for diabetes and 156 
all its complications simultaneously and embed DR screening within the primary care.  157 
 158 
Rationale for an Implementation Strategy 159 
Each aspect of the DR screening and care pathway has to be adapted to local needs and 160 
resources, requiring a locally appropriate implementation strategy. For example, mydriasis 161 
(pupil dilatation) is compulsory in some screening programmes but not in others and this 162 
process requires local approval by stakeholders. 10-12  In Kerala, mydriasis needs to be approved 163 
by the health department. Other issues faced by low and middle income countries are that the 164 
number of undiagnosed diabetes cases is high, 13 the non-availability of a state-wide diabetes 165 
register with recall facilities, the lack of resources for standardised non-portable retinal cameras, 166 
limited capacity of staff in primary care to screen for DR, and that the number of people with 167 
diabetes is larger than the capacity of the services provided by the secondary care hospitals. 14-168 
16 Research capacity and capability are in their infancy in LMICs and implementing change in a 169 
busy environment when demands on staff are great and resources are limited is challenging. 15, 170 
16 In addition, as cataract is more prevalent in low and middle income countries, 17 the 171 
proportion of ungradable retinal images is higher compared to developed countries. 17-19 172 
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Therefore, we need to evaluate the implementation strategy using both qualitative and 173 
quantitative methods. 20-22 174 
   175 
Aims and Objectives 176 
The Nayanamritham study is facilitated by a UK-Government of Kerala partnership as a part of 177 
the ORNATE-India project funded by Global Challenges Research Fund (GCRF) and UK 178 
Research and Innovation (UKRI). We aim to introduce a DR care pathway that spans primary, 179 
secondary and tertiary care in the public health system in Kerala in a pilot study in 180 
Thiruvananthapuram. The proposed study will (1) examine the clinical and cost effectiveness of 181 
the DR care pathway at the patient, clinician and service levels and (2) evaluate the 182 
implementation strategy of the pathway.  183 
 184 
METHODS 185 
Design: We chose a type 2 hybrid effectiveness-implementation design to evaluate the 186 
effectiveness of the clinical interventions and the implementation strategies. 20-23 Mixed methods 187 
will be used as the method of evaluation. DR care pathway was developed by the Kerala Health 188 
Secretary, non-communicable diseases lead, Health and Medical Education service providers, 189 
technical and EHR teams, local authorities and the GCRF/UKRI- funded co-applicants from the 190 
UK. The DR care pathway will be set-up in a staggered approach with 5 family health centres 191 
initiated in the first three months and the remaining 11 centres will be added based on 192 
acceptance of all stakeholders and adapting and training phase for 12 months from 15-03-2018. 193 
A further 12-15 months will be allocated to recruit consenting patients to a cross-sectional study 194 
to gather quantitative data for the effectiveness outcomes.  A minimal dataset from this study 195 
will also be entered into EHR to enable future screening for the consented patients. Qualitative 196 
data collection from interviews of staff, patients and focus groups at baseline and end of study 197 
and all field notes gathered during the study will be utilised to inform evaluation of the 198 
implementation strategy. 20-22 199 
 200 
Target Population 201 
People with diabetes registered in the non-communicable diseases register at 16 family health 202 
centres in Thiruvananthapuram district will be invited to be screened for complications of 203 
diabetes including screening for DR. As the non-communicable diseases register is likely to 204 
show an increase in newly diagnosed diabetes as a result of training the accredited social 205 
health activists (ASHAs), in diabetes and DR, we will evaluate the effectiveness of the complex 206 
 
 7 
interventions delivered at each of the 16 family health centres for this study. The implementation 207 
of the pathway will take into account all patients in the  non-communicable diseases register at 208 
the start of the cross-sectional study.  209 
 210 
Setting 211 
Target sites for implementation of DR screening and treatment in Thiruvananthapuram will 212 
include 16 family health centres for DR screening which represents the primary care centres 213 
where patients are screened for all complications of diabetes. The retinal images, captured by 214 
the trained, resident nursing staff will be sent to a newly developed reading centre at the 215 
Regional Institute of Ophthalmology, a tertiary care centre, where newly accredited graders will 216 
grade the images. Patients with screen-positive images will be referred to three secondary care 217 
hospitals (district hospitals). Severe cases that require complex interventions will be referred to 218 
the tertiary care centre, the tertiary for specialist management of DR.  219 
 220 
Description of the standard of care 221 
Currently, patients with diabetes are not systematically screened for DR in the public health 222 
system. Most patients present to the tertiary centre voluntarily either because of increased 223 
awareness of complications of diabetes or due to visual impairment.  Therefore, the current 224 
standard of care will be captured as the number of patients presenting to the tertiary centre for 225 
an eye consultation for DR over a period of time as there is no baseline data in the primary and 226 
secondary care. This cross-sectional survey of the patients presenting at the family health 227 
centres  will provide information on the uptake of screening of people registered in the  non-228 
communicable diseases register at the start of the study. The prevalence of DR and STDR of 229 
the screened population will be estimated from the numbers screened in all the  non-230 
communicable diseases registers during this period.  231 
Evidence-based clinical intervention:  232 
The new DR care pathway is the intervention and is shown in Figure 1. The pathway will span 233 
primary, secondary and tertiary care. The components of the pathway are:  234 
1. DR screening of patients with diabetes registered in the  non-communicable diseases 235 
register at family health centres (primary care).  The retinal images will be graded 236 
remotely at the reading centre at the tertiary centre. 237 
2. Prompt referral for timely treatment of STDR to secondary care and tertiary centres 238 
depending on the severity of the DR. 239 
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3. Treatment of patients with sight threatening DR (at secondary and tertiary care). 240 
 241 
Implementation strategies 242 
The implementation strategies of the new DR care pathway are categorised as shown in Table 243 
1 into plan, finance, education, infrastructure, quality improvement and policy contexts. These 244 
categories are developed based on the discrete Expert Recommendations for Implementing 245 
Change (ERIC) taxonomy.20, 21 The logic model is shown in Figure 2.  246 
 247 









Plan Conduct local needs 
assessment 
The study team will conduct a situational 
analysis of data from self-referred patients.  
Assess for readiness and 
identify barriers and 
facilitators 
Assess barriers that may impede 
implementation of the DR care pathway, and 
strengths that can be used in the 
implementation effort by interviewing key 
stakeholders i.e. family health centres staff, 
ophthalmologists in secondary and tertiary 
care, health service employees and patients.  
Develop a formal 
implementation blueprint 
The blueprint will be used to guide the 
implementation of the whole DR care 
pathway and will be updated with time.  
Tailor strategies Regular collaborative meetings will be held 
to tailor the implementation strategies to 
address barriers and leverage facilitators 
that are identified during various steps in the 
implementation.  
Stage implementation 
scale up and integration 
The implementation will be staggered with 
five family health centres  starting as pilots to 
enable small changes before gradually 
moving to other 11 centres. Addition of more 
centres during the staggered phase will be 
considered as sign of acceptability and 
feasibility.  
Ensure integration of the DR care pathway 
into EHR. In the long-term, the adoption of 
the DR care pathway across the state of 
Kerala will be considered as success. 
Build a coalition Cultivate relationships with staff at family 
health centres and secondary care centres, 
data entry operators, EHR team, project 
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manager, and the Government of Kerala 
health service departmental staff in the 
implementation effort and create a learning 
system to incorporate practitioner feedback.  
Develop academic 
partnerships 
Partner with UK academic institutions for the 
purposes of shared training and bringing 
research skills to the implementation of the 
pathway.  
Recruit, designate, and 
train for leadership 
A project manager will be recruited to 
manage the programme under the 
supervision of the  non-communicable 
diseases lead. The Health Secretary will 
conduct periodic meetings with the project 
team to assess performance.  
Obtain formal 
commitments 
A collaborative agreement is in place 
between Government of Kerala and 
Moorfields Eye Hospital, London, UK  
outlining their roles and responsibilities in the 
implementation of the DR care pathway.  
Prepare patients to be 
active participants 
Community level health workers will prepare 
patients to be active in their care, to ask 
questions, and specifically to inquire about 
care guidelines, the evidence behind clinical 
decisions, or about available evidence-
supported treatments. Each patient will 
provide written consent to be screened for 
DR in this project as well as participate in 
interviews after verbal consent.  
Inform local opinion 
leaders 
The Health Minister of the Kerala state and 
members of the local government will be 
briefed on the project and encouraged to be 
champions of the project to enable scale up 
to all family health centres in the state.  
Finance  Access new funding Use GCRF/UKRI funding to purchase 
smartphone retinal cameras and retinal 
lasers, develop EHR, train staff at family 
health centres and secondary care, employ 
project manager, data entry operators and 
personnel to conduct interviews, create 
study database linked to hand-held 
applications for data entry operators. State 
and local government funds will be sourced 
for scale up.  
Incentivisation ASHAs will be incentivised to accompany 
participants with diabetes who are referred to 
secondary care for treatment.  
Education  Develop educational 
materials  
Develop DR training modules and retinal 










Distribute educational materials (including 
guidelines, manuals, and toolkits) in person, 
by mail, and/or electronically. Multiple 
training sessions are planned at each family 
health centres. The camera manufacturers 
will be invited to provide hands-on training 
on capturing good quality retinal images. 
Training on laser surgery will also be 
provided to the ophthalmologists at 
secondary care.  
Conduct educational 
meetings 
Hold meetings targeting different stakeholder 
groups (ophthalmologists,  family health 
centres staff, ASHAs, patients). Three 
educational meetings are planned by the UK 
team to meet with the providers in the family 
health centres settings to share knowledge 
and educate providers about the DR care 
pathway and its integration into their clinical 
practice.  
Achieve accreditation for 
graders of retinal images 
Train and certify the optometrists in the 
Reading Centre in the tertiary centre to 
obtain accreditation as graders using the 
online international Test and Training for 
retinal graders.  
Conduct ongoing training Nurses and doctors in the family health 
centres will receive on-going training on DR, 
pupil dilatation and capture of retinal images 
using low-cost smartphone retinal 
cameras.24, 25  
Create a learning 
collaborative 
The Health Secretary of State will foster a 
collaborative learning environment to 




The UK team will first train a batch of family 
health centres nurses to capture retinal 
images and then some will be trained to train 
the rest of the nurses. The same cascading 
pathway will apply to laser training.  
Work with educational 
institutions 
Moorfields Eye Hospital staff will provide the 
necessary guidance and share knowledge 
on UK diabetic retinopathy screening 
pathway.  
Make training dynamic All staff involved will receive continual online 
or face to face training.  
Increase demand The ASHAs will be trained to increase public 
awareness of this pathway in their house-to-





The UK team from Moorfields Eye Hospital 
will provide ongoing consultation to support 
implementation of DR care pathway.  
Infrastructure  Centralize technical 
assistance 
The project manager and the EHR team will 
provide central assistance focused on 
implementation issues. The telemedicine 
project will link the patient’s retinal images to 
EHR and transfer through a secure cloud to   
the tertiary centre, where the images will be 
graded for their DR status in a newly 
developed reading centre, with the results 
fed back to the family health centres.26  
Change physical structure 
and equipment 
Evaluate current configuration of family 
health centres consulting rooms to allow 
suitable furniture for cameras and adapt 
illumination to capture retinal photographs.  
Change record systems Change records systems to allow better 
assessment of implementation or clinical 
outcomes by having data entry operators 
interview patients and input full data into 
EHR within the busy family health centres 
clinics.  
Change service sites Change the timetable for clinics in secondary 
care to allow a patients referred from primary 
care to access treatment.  
Revise professional roles The non-communicable diseases lead will be 
delegated to take on the responsibility of 
implementing this DR care pathway in 
Thiruvananthapuram aiming for  a Kerala 
state-wide roll out.  
Quality 
Improvement 
Develop and implement 
tools for quality monitoring 
Develop, test, and introduce into quality-
monitoring systems the right input—the 
appropriate language for the consent form, 
protocols on DR screening, grading retinal 
images, and measures of processes, patient 
outcomes, and implementation outcomes.  
Develop and organize 
quality monitoring systems 
Develop and organise systems and 
procedures that monitor clinical processes 
and/or outcomes for the purpose of quality 
assurance and improvement.  
Audit and provide feedback Collect and summarise clinical performance 
data every month and feedback to family 
health centres  and secondary care staff to 
monitor, evaluate, and modify pathway for 
acceptability to patients and staff. A 
continuous monitoring of retinal image 
quality and gradability, and the referral 
pathway will be done to cyclically input 
change into the DR pathway to improve the 
quality and integration.  
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Conduct cyclical small 
tests of change 
Staggered set up of family health centres  to 
allow implementation of changes in a cyclical 
fashion using small tests of change before 
taking changes system-wide. Tests of 
change benefit will be measured continually 
by increase uptake of training, screening, 
referral and treatment.  
Use data experts The EHR team will develop an application for 
the data entry operators to collect data. The 
UK collaborators will collaborate in the 
analysis of the data.  
Use data warehousing 
techniques 
Integrate clinical records from this research 
project into EHR on an on-going basis.  
Capture and share local 
knowledge 
Capture local knowledge from 
implementation sites on how staff and 
doctors make something work in their family 
health centres  and then share it with other 
centres.  
Obtain and use patients  
feedback 
The participating patients will be asked to 
provide feedback on the implementation 
effort.  
Promote adaptability Identify ways the DR care pathway can be 
tailored to meet local needs and clarify which 
elements of the pathway must be maintained 
to preserve fidelity.  
Provide clinical supervision The Director of the tertiary centre will provide 
the overall clinical supervision of the whole 
DR care pathway. He will also delegate 
ophthalmologists to provide ongoing 
supervision for the optometrists involved in 
grading retinal images.  
Provide local technical 
assistance 
Develop and use a system to deliver 
technical assistance focused on 
implementation issues using relevant service 
providers.  
Purposely re-examine the 
implementation 
Monthly monitoring of screened patients at 
each family health centre, barriers observed 
and small changes that are required will be 
implemented to continuously improve the 
pathway.  
Remind clinicians Primary care doctors in family health centres  
will receive monthly newsletter on the 
numbers recruited across all centres to 
highlighting successes and providing 
potential solutions to issues encountered.  
Policy contexts Issue Government of 
Kerala approval to enable 
dilatation of pupils of 
patients under supervision 
Ensure doctors at family health centres 
receive approval for mydriasis in order to 
deliver the DR care pathway.  
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of family health centres 
doctors  
Mandate change The Health Secretary of State will provide 
leadership to ensure the prioritisation of the 
implementation of the DR care pathway.  
 
DR-diabetic retinopathy; ASHAs -accredited social health activists; GCRF/UKRI -Global 249 
Challenge Research Fund/UK Research and Innovation; EHR –Electronic health records. 250 
Outcomes  251 
 252 
Pre-specified outcomes of the effectiveness of the DR pathway and the evaluation of the 253 
implementation strategy are tabulated in table 2 and table 3, respectively. 254 
 255 
Table 2: DR pathway- (intervention) related outcomes 256 
 257 
Outcomes  Indicators  Source of data  
Clinical 
Effectiveness 
− Proportion of people screened for DR in 
each family health centres over 12 
months. 
− Proportion of referred patients with 
STDR. 
− Proportion of ungradable retinal images 
and percentage of cataract identified 
from referring these patients. 
− Risk and complication burden in people 
screened for DR 
− Presenting visual acuity of those 
referred from the DR pathway 
compared to those who self-referred to 
secondary care.  
− Generalisability of the prevalence data 
compared to house-to-house survey in 
a neighbouring district.  
 
Data from monthly entries 
into EHR and study 
database. 
−  





The key outcome is the number of cases 
of severe visual impairment or blindness 
due to STDR averted as a result of the 
new DR care pathway and resultant 
QALY gain. 
Estimated QALY gain from laser 
treatment of STDR and from cataract 
surgery, using utility values from 
Rachapelle et al 2013.27  
Assumption that the effect of no 
screening is as in historic studies that 
reported the rate at which STDR leads to 
blindness if left untreated.  
Data collected in the study, 
data from the literature and 
expert opinion where data 
could not be collected.   
 
Efficiency Efficiency is defined as optimal use of the 
service. For this purpose, we will first 
estimate the time required to process one 
patient from the path-process analysis. 
This estimate will be used to determine 
the number of patients who can be seen 
on a day. We will then calculate (1-
number of patients screened)/number of 
patients that can be screened). 
proportion can be used in a p-type control 
chart.28 
 
Capture efficiencies in 
structures, resources and 
processes across the DR 
care pathway from staff 
interviews. 
 
Path process mining of 
patients screened in family 
health centres  analysis will 
be based on detailed time-
event logs of approximately 




Patients willingness to be screened and 
their satisfaction with the information 
provided to them and the care they 
received 
 
Patient interviews and 
telephone survey of patients 
referred to secondary care  
for treatment 
Timeliness Path process mapping at family health 
centres to understand delays in pathway 
Reasons for non-attendance for those 
referred to secondary care for treatment 
of STDR 
Path process mapping at 
family health centres  to 
understand delays in DR 
care pathway 
 
Patient survey and 
secondary care records  
Equity  Age and gender-based prevalence of DR 
and STDR will be reported on consented 
patients from all family health centres. 
Reasons of non-referral of patients that 
require referrals will be recorded. 
Numbers denied screening despite 
willingness to be screened will also be 
reported. 




 DR -diabetic retinopathy; STDR-sight threatening diabetic retinopathy; QALY- quality-adjusted 258 
life year 259 
 260 
Table 3: Outcomes of the evaluation of the implementation strategy 261 
 262 
Outcomes Indicators  Assessment and data source  
Acceptability Willingness of each 
family health centres to 




























Patients acceptability of 
the pathway  
Assessment: Readiness to implement the DR 
care pathway in the 16 family health centres  
and any reasons for delay. 
Data source: Clinical performance from family 
health centres that will include monthly uptake 
of DR screening at each  centre and any reports 
on barriers causing delays in implementation 
provided by the project manager.  
 
Assessment: Proportions of trained ASHAs, 
nurses and doctors per family health centres, 
increase in doctors trained in laser surgery in 
secondary care, proportions willing to be 
included in train the trainer programme. The 
denominator will be total numbers of each 
personnel available to be trained on the date of 
implementation.  
 
Data sources: Accreditation and certification 
records; Structured interviews of at least 5 
nurses and 5 primary care doctors from 16 
family health centres, 3-5 ophthalmologists from 
secondary and tertiary care, 2 data entry 
operators and 5 ASHAs and 1 health service 




Assessment: Screening attendances per 
family health centres over 12 months. 
 
Data sources: Clinical performance data and a 
telephone questionnaire survey for screened 
and referred patients to evaluate reasons for 
attendance and non-attendance.  
 
Adoption Uptake of DR care 
pathway at primary, 




Uptake of training by 
staff  
Assessment: Proportion of staff at primary, 
secondary and tertiary care willing to integrate 
DR care pathway in their workload. 
 










Uptake of screening 





Adoption of DR care 
pathway by the 




Assessment: Demand training sessions; 
Attendance rates at training sessions 
 
Data source: number of training sessions and 
attendance registers at training sessions. 
 
 
Assessment: Increase in proportions of patient 
screened over 12 months. 
 
Data source: EHR and study database.  
 
 
Assessment: A policy paper by the 
Government of Kerala for state-wide adoption of 
the DR care pathway as part of diabetes care 
for all patients. 
 
Data source: A detailed scale-up plan will be 
developed for each district based on the clinical 
and cost-effectiveness data from this study to 
inform policy. 
Appropriateness  Appropriateness of 
family health centres  
for DR screening 
  
Appropriateness of the 
complex DR care 
pathway across primary 




referrals to secondary 
care 
Assessment: Qualitative data on barriers and 
facilitators of the delivery of screening and 
treatment in secondary care.   
 
Data sources: interview of staff at family health 
centres  and secondary care, pPatient 
telephone survey on pathway from FHCs to 
secondary care  
 
Assessment: False positive referrals from data 
collection at secondary care.  
 
Data sources: study database; data from patient 
telephone survey 
Cost  Costs to the 
Government of Kerala 
and societal costs of 
the DR screening 
programme and 
subsequent treatment   
 
Assessment: Costs of the DR screening and 
treatment costs in total and per person, 
including the costs of staff training and cameras 
(suitably annuitized), staff costs and travel costs 
of patients.   
 
Data sources: Data collected in the study 
baseline and data from other services in India 
and from the literature.   
Feasibility Screening rate per 
family health centres 
Barriers to monthly 
screening uptake  
 
Assessment: Monthly increase in numbers of 




Data source:Interview and monthly report from 
project manager on facilitators and barriers on 
each part of the pathway 
 











Validation of the DR 








Delivery of training and 
the impact on the DR 
care pathway 
Assessment: Fidelity evaluation in 16 family 
health centres  using a path-process analysis of 
the screening to identify the common screening 
pathway across centres .  
 
Data source: The path-process analysis will be 
based on detailed time-event logs of 70 patients 
from the 16 family health centres; a telephone 
follow-up of referred patients to evaluate uptake 
of referrals.  
Assessment: Validation of the DR grading will 
be assessed by the agreement of the DR grade 
reported by the optometrists at the reading 
centre in the tertiary centre and those reported 
by the ophthalmologists in the secondary care 
centres.  
                   
Data sources: DR grading of referred patients 
obtained from the reading centre versus 
secondary care. 
 
Assessment: Increase in numbers of trained 
staff per month. 
 
Data sources: Staff interviews, structured 
observations and review of facility records. The 
proportions of doctors trained on laser delivery; 
data quality on the database; Increase in  non-
communicable diseases registration following 
start of programme due to training of ASHA 
workers on diabetes and DR; Increase in 
numbers of patients treated for STDR following 
training. 
Penetration Increase patient 
awareness of diabetes 
and DR and uptake of 
the DR screening 
pathway in patients 
with diabetes  
Assessment: Increase uptake of DR screening 
by patients registered in non-communicable 
diseases registers.  
 
Data sources: from non-communicable 
diseases register and EHR 
 
Sustainability  Policy makers to 
prepare policy on up-
scale and sustainability 




Assessment: Availability of a policy paper from 
Government of Kerala on state-wide scale up of 
the DR care pathway. This will be considered a 
success of the programme. 
 
Data sources: Scale up plan for other districts 







Integration of DR 
pathway in weekly 
activities in FHCs 
 
acceptance of guidelines and training material 
for state-wide roll out. 
 
Assessment: Integration of DR pathway in 
EHR  
 
Data source: EHR records of DR screening as 
part of  non-communicable diseases care 
pathway. 
 
DR-diabetic retinopathy; ASHA -accredited social health activists, EHR- electronic health 263 
records  264 
 265 
 266 
Data collection  267 
Quantitative data 268 
Effectiveness outcomes will originate from the data sources shown in table 2. Data collected by 269 
nurses or data operators from the EHR include age, gender, duration of diabetes, use of insulin, 270 
parental history of diabetes, other complications of diabetes including diabetic kidney disease, 271 
cardiovascular complications, and diabetic foot, random blood sugar results, urine dipstick test 272 
for albuminuria and blood pressure record. Other study-specific data collected by nurses or data 273 
operators on the day of screening include education status, occupation and income categories, 274 
and previous history of DR, cataract surgery or any other ocular history. In addition, they will 275 
measure body mass index, waist circumference and complete a lifestyle questionnaire on 276 
smoking, diet, physical activity, EQ-5D vision bolt-on29. The EQ-5D vision bolt-on will be used to 277 
calculate the quality adjusted life-years and utility value for economic analysis. EQ-5D alone 278 
does not capture visual acuity deficits.30 The EQ-5D vision bolt-on asks patients to rate their 279 
health across 6 dimensions: mobility, self-care, usual activities, pain/discomfort, 280 
anxiety/depression and vision. Each dimension is scored in 5 levels: no problems, slight 281 
problems, moderate problems, severe problems, and extreme problems. A recent study 282 
provided utility values based on EQ-5D vision bolt-on. The mapping was done in a clinical trial 283 
cohort with macular oedema in central retinal vein occlusion. 31 284 
In the reading centre, the data collection will include the grade of retinopathy in both eyes, 285 
presence of cataract and gradability of the retinal images. Data collected on referred patients 286 
will include numbers with ungradable images due to cataract, treatment options offered for DR 287 
and review appointment.  288 
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Qualitative data collection and analysis  289 
Data sources used for evaluation of the implementation strategy are shown in table 3. These will 290 
include data from a structured interview of a maximum variable sample that will reflect the 291 
context (primary, secondary and tertiary care), and the functions and skill levels of the staff (e.g. 292 
nurses, doctors etc.). Based on pragmatic considerations, at least 5 nurses and 5 primary care 293 
doctors from 16 FHCs, 3-5 ophthalmologists from secondary and tertiary care, 2 data entry 294 
operators and 5 ASHAs and 1 health service administrator should be included to get the 295 
maximum variability.  Verbal consent will be obtained from these health professionals. The 296 
interviews will be conducted by an independent member from the GCRF/UKRI-funded team, 297 
who is not involved in this study, in the local language within the premises of the healthcare 298 
provider. The focus group will consist of groups of patients and staff within one family health 299 
centres. In addition, to the voice-recording of the interviews and focus group, interviewers will 300 
write field notes to describe the interview situation. The interviews and focus group content will 301 
provide the basis for the data analysis, which will be based on a descriptive phenomenological 302 
approach without data or opinion interpretation and will include transcription, condensation, 303 
coding and categorisation using qualitative analysis tools. We will use the field notes collected 304 
during the interviews to inform the understanding of the phenomenon studied. 305 
A survey of all referred patients will be done using a structured questionnaire to evaluate their 306 
satisfaction and their perception of the barriers and facilitators. All qualitative data will be coded 307 
using NVivo and analysed using descriptive phenomenological approach following the 308 
strategy.32 We will transcribe the interview data, identify  statements or phrases, create 309 
formulated meanings or meaning units, aggregate formulated meanings and incorporate the 310 
result into descriptions. 311 
 312 
Data Monitoring 313 
Data will be coded before entry into the study database by the clinical teams. Only anonymised 314 
extracted data from EHR by the nurses or data entry operators will be used for analysis. Data 315 
quality will be monitored by the study project manager. Anonymised data will be checked for 316 
range checks and data quality at University of East London by the study statistics team. The 317 
ORNATE India International Advisory Board will have an overview of the conduct of the project 318 
and the Executive Group consisting of the UK-India collaborators will monitor the conduct of the 319 
study.  320 
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Sample size 321 
We have chosen the proportion of patients in the non-communicable diseases register with 322 
diabetes screened for DR as our primary outcome variable.  323 
Justification of the choice of primary outcome: This variable captures the effectiveness of our 324 
intervention as well as the fidelity of implementation. Other facts that informed our choice of the 325 
primary outcome is that we expect a short implementation time of 7 to 9 months during which 326 
other outcomes such as number of patients treated may not be a feasible option. Therefore, we 327 
have estimated the sample size based on this primary outcome. 328 
Our calculations are complicated by the expected increase in number of people with diabetes in 329 
the  non-communicable diseases register as public awareness of diabetes and DR increases so 330 
the denominator of numbers screened will be the number of people registered in the  non-331 
communicable diseases in each family health centres at the start of the cross-sectional study. 332 
There is no data on the baseline proportion of patients that attend the tertiary centre for 333 
screening. The prevalence of diabetes is between 10-16% in Thiruvananthapuram of which 8% 334 
are estimated to have DR and 3% to have STDR but about 20% may have to be referred. 335 
Assuming a finite population of 40,000 patients with diabetes, a simple random sample of 377 336 
patients will be needed. However, we expect large design effects due to clustering patients 337 
within family health centres. There is not enough data to calculate the value of this design effect 338 
and therefore we assume it to be 3 to give a final sample size of 1,131, which is equivalent to 339 
assuming a within-family health centres intracluster correlation coefficient of approximately 0.03 340 
(n=16 family health centres) with negligible residual clustering by the intermediate cluster level 341 
of ASHAs, where mean cluster size is smaller. 342 
As described by Becker et al in mammography screening,33 we expect sources of bias in the 343 
implementation programme that will likely influence the sample size calculation. Unscreened DR 344 
cases that already exist in the community may contribute to an over-estimation of the effect of 345 
screening. We expect lead-time bias because of our short implementation period and so some 346 
DR in the community may be missed. A comparison of numbers with DR in family health centres 347 
with longer implementation period with those of shorter period may adjust for this bias. We 348 
intend to provide a descriptive analysis as well as a temporal comparison using time series 349 
analysis.  350 
Statistical Analyses 351 
We will create a complete case dataset of the cross-sectional survey for use in the analyses of 352 
effectiveness and assess the potential impact of missing data using sensitivity analysis 353 
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incorporating a range of optimistic and pessimistic scenarios for the impact of missing data. We 354 
will model two outcomes that we hypothesised would be influenced by the intervention: (1) 355 
uptake of DR screening (primary outcome) and (2) numbers of patients referred for STDR as a 356 
result of screening. We will use bivariate logistic regression models to assess crude 357 
associations between sociodemographic factors such as age, gender, education, income, and 358 
living arrangements, and other clinical data with DR and STDR and use fractional polynomials 359 
to account for the form of continuous covariates to predict uptake of DR screening.  Factors 360 
associated with a P<0.25 will be candidates for inclusion in the multivariable logistic regression 361 
models. We will test interactions amongst identified main effects to capture improvement in 362 
model prediction assessed by reduced residual variance-based statistics. To account for the 363 
staggered entry into the study, we will add a variable indicating the month of entry of each family 364 
health centres into the programme (e.g., 1. if the family health centre join in the first month of 365 
the programme, 2. if in the second month and so on). A non-significant coefficient for this 366 
variable will suggest the staggered approach had no effect and a significant coefficient will allow 367 
the effect to be quantified for each family health centre. In our final adjusted model, we will 368 
consider associations with a P<.05 as statistically significant. Adequacy of model discrimination 369 
and calibration will be assessed using Receiver Operating Characteristic (ROC) curves. The 370 
validation of the telemedicine will be reported as the agreement (kappa statistics) between 371 
screen positive patients graded by the graders at the reading centre versus the DR grade as 372 
recorded by the ophthalmologists in secondary care centres. A kappa coefficient of 0.6 or higher 373 
was pre-specified to indicate validity.  374 
 375 
Patient and public involvement (PPI) 376 
A patient and public group will be involved in plans to disseminate the study results and provide 377 
their input on the scale-up of this DR care pathway, should the implementation in 378 
Thiruvananthapuram be deemed successful by the Government of Kerala.  379 
 380 
Ethics and dissemination 381 
The study was approved by Indian Medical Research Council (2018-0551). The study complies 382 
with the guidelines of the Declaration of Helsinki. Results of this research are expected to be 383 
disseminated through stakeholder reports and via scientific forums, specifically peer-reviewed 384 
publications and conference presentations. All participants will give written informed consent 385 
prior to entry to the study by the family health centres nurses and will be made aware that 386 





At the conclusion of this study, we hope to assess the effectiveness and implementation 390 
outcomes of a complex DR care pathway integrating care at primary, secondary and tertiary 391 
care, covering a proportion of the diabetic population in Thiruvananthapuram. The study will set 392 
the scene for a policy for State-wide Screening and Treatment Pathway for Diabetes. Early 393 
identification of STDR and other complications due to this holistic approach and timely 394 
treatment, are expected to have a positive impact on rates of blindness, chronic kidney disease, 395 
cardiovascular complications and thereby improve health, reduce multi-morbidity and mortality. 396 
A DR pathway that straddles primary, secondary and tertiary levels of care, leveraging 397 
technology may have advantages of cost effectiveness and ease of implementation in low and 398 
middle income countries compared to the current practice of detection and management of self-399 
reported cases in tertiary centres.  400 
This study outlines how the effectiveness of a DR care pathway and its implementation will be 401 
evaluated. 21, 22 This study is timely given the increasing numbers of people with diabetes and 402 
pressure on finances available for healthcare, necessitating task shifting to enable better 403 
coverage of the population.. The study will also examine the organisation functions such as 404 
structure, resources and processes that would contribute to better outcomes. We will also 405 
examine whether this additional task is feasible given the current skill levels and workload of 406 
family health centres and secondary hospitals. The study will reveal whether current health 407 
seeking behaviour of patients will support screening, especially when an invasive procedure is 408 
requested when there is no obvious impact on quality of life of the patient. By addressing a key 409 
gap in knowledge due to lack of research in this area, we will be able to decipher the barriers 410 
and facilitators that influence the successful implementation of such a programme in the public 411 
system in India. The results of this study may inform the adoption of this pathway in other areas 412 
in India and globally. However, the complexity and number of implementation strategies, local 413 
contextual factors and lack of validated implementation outcomes may limit generalisability of 414 
the results and implementation of this pathway elsewhere.  415 
There are limitations, however, to the study design. We do not have baseline data on DR 416 
screening in the study location as these screening programmes are non-existent. For this 417 
reason, we are examining the effectiveness of the pathway in terms of presenting visual acuity 418 
for referable cases as ‘proximal’ outcomes. In addition, when there is no concurrent control 419 
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group, causal inferences are difficult to make and may lead to both measured and unmeasured 420 
biases. When examining implementation, logistical issues, variations in health care facilities, 421 
socio-economic variation, and quality of health care personnel may likely affect our study. 422 
However, the study design avoids the ethical challenges of having a control group with no DR 423 
screening. Therefore, the study design is by necessity non-randomised and observational and 424 
will rely on newly trained staff members to collect data, which is likely to differ in completeness 425 
between the 16 family health centres. We expect an increase in referral rates after 426 
implementation of the intervention due to better public awareness, increasing knowledge of 427 
ASHAs and improved case ascertainment, at least in some family health centres . We will also 428 
examine the impact of cataract in the community and this has not been studied before in any 429 
other DR pathway. We have tried to minimise the limitations by the use of robust statistical 430 
techniques and the use of various data sources to elicit a greater understanding of how the 431 
programme will lead to better health outcomes.  432 
One of the strengths of this study is that   quantitative data backed by qualitative data will be 433 
collected to strengthen our findings and enable generalisation of our findings. Secondly, we will 434 
use robust statistical methods to reduce bias including selection bias and other confounders. 435 
Finally, the access to and collaboration with the UK is a key strength of the study, as it facilitates 436 
the co-development of the interventions from the outset. Active involvement of policy makers 437 
engaged in transformation of primary care to screen for and address complications of  non-438 
communicable diseases  who value research to generate evidence for policy making and who 439 
are prepared to learn from, and adapt the DR care pathway based on implementation 440 
experience is a unique feature of this study.. Findings on the mechanisms and contexts that 441 
optimise the implementation of this complex multi-faceted intervention using the ERIC taxonomy 442 
will be useful to those developing and implementing these programmes in other health systems.  443 
The health economic model may highlight the health expenditure required at individual, family 444 
and Kerala State level for forecasting and planning health budgets.  445 
Perhaps the most important aspect of the chosen evaluation is that it is built within a 446 
simultaneous developing public health strategy on population-based screening of diabetes and 447 
hypertension and a recently introduced EHR called eHealth. Conducting research in such an 448 
environment is a good example of health policy and systems research.  449 
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Despite the limitations, this study holds promise for providing high-quality data and detailed 450 
implementation information on a complex intervention in a resources-limited setting. We hope to 451 
contribute to the literature on the implementation and effectiveness of DR screening and 452 
treatment in the public health sector in low and middle income countries.  453 
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